drugset / Trial / NCT00471536
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-07
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 800 mg | Oral |